Evidence map›Paper›PMID 39415916›Full record

ArticleEJHaem2024

Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives.

Bert Heyrman, Stef Meers, Sélim Sid, Natalie Put, Koen Theunissen, Koen Van Eygen, Nathan De Beule, Maxime Clauwaert, Helena Maes, Alexander Salembier and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Bert HeyrmanDepartment of Haematology Ziekenhuis Netwerk Antwerpen Antwerp Belgium.ORCID https://orcid.org/0000-0001-5816-5375
Stef MeersDepartment of Haematology Algemeen Ziekenhuis Klina Brasschaat Belgium.ORCID https://orcid.org/0000-0003-1754-2175
Sélim SidDepartment of Haematology Centre Hospitalier Régional Verviers Verviers Belgium.
Natalie PutDepartment of Haematology Ziekenhuis Oost-Limburg Genk Belgium.
Koen TheunissenDepartment of Haematology Jessa Ziekenhuis Hasselt Belgium.
Koen Van EygenDepartment of Haematology Algemeen Ziekenhuis Groeninge Kortrijk Belgium.ORCID https://orcid.org/0000-0001-8285-906X
Nathan De BeuleDepartment of Haematology Universitair Ziekenhuis Brussel Jette Belgium.
Maxime ClauwaertDepartment of Haematology Algemeen Ziekenhuis Sint-Lucas Gent Belgium.
Helena MaesDepartment of Haematology Imelda Ziekenhuis Bonheiden Belgium.
Alexander SalembierDepartment of Haematology Algemeen Ziekenhuis Glorieux Ronse Belgium.
Jan LemmensDepartment of Haematology Gasthuiszusters Antwerpen Antwerp Belgium.
Ann Van De VeldeDepartment of Haematology Universitair Ziekenhuis Antwerpen Edegem Belgium.ORCID https://orcid.org/0000-0002-4579-2916
Dominik SelleslagDepartment of Haematology Algemeen Ziekenhuis Sint-Jan Bruges Belgium.
Jason BouziotisClinical Trial Center Universitair Ziekenhuis Antwerpen Edegem Belgium.
Ann De BeckerDepartment of Haematology Universitair Ziekenhuis Brussel Jette Belgium.
Sébastien AnguilleDepartment of Haematology Universitair Ziekenhuis Antwerpen Edegem Belgium.ORCID https://orcid.org/0000-0002-1951-6715

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39415916
PMCPMC11474394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.